Eye-Related Adverse Events After I-131 Radioiodine Therapy: A Systematic Review of the Current Literature
Authors' conclusion
The risk of ophthalmic complications is associated with various factors, including the administration of high I-131 doses, age of more than 45 years, and time to event within the first 12 months. Considering these conditions may help enhance patient care and prevent adverse outcomes that may limit patients' quality of life.
Study context
- Population
- Patients with thyroid cancer receiving I-131 radioactive iodine (RAI) therapy; PubMed, Scopus and Web of Science searched until October 202328 studies
- Outcome
- Ocular complications (eye-related adverse events) of RAI therapy
Methodological detailsPRISMA-based
- PRISMA-based
Pooled result
As reported in the abstract
Ophthalmic symptoms after RAI therapy
Obstructive diseases (e.g. nasolacrimal duct obstruction), median incidence rate
6.8%
Inflammatory symptoms, median incidence rate
13%
Cataracts, median incidence rate
2.5 and 5%
Original publication
Eye-Related Adverse Events After I-131 Radioiodine Therapy: A Systematic Review of the Current Literature. Endocr Pract. Published 30 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →